S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   298.36 (-2.55%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   298.36 (-2.55%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   298.36 (-2.55%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   298.36 (-2.55%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
LON:REDX

Redx Pharma (REDX) Share Forecast, Price & News

GBX 59.25
-1.75 (-2.87%)
(As of 05/18/2022 03:20 PM ET)
Add
Compare
Today's Range
58
60
50-Day Range
58.80
77.45
52-Week Range
52
129.90
Volume
8,768 shs
Average Volume
16,927 shs
Market Capitalization
£163.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive REDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Redx Pharma logo

About Redx Pharma

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Headlines

Redx Pharma to present oncology drug to ASCO gathering
Redx Pharma hails pre-clinical data on cancer asset
Redx Pharma plc : Redx to Receive Milestone Payment of $9m from AZ
Redx Pharma plc : Redx to Participate at Piper Sandler Conference
Redx Pharma plc : Redx to Present at Jefferies London Conference
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
71
Year Founded
N/A

Sales & Book Value

Annual Sales
£10.04 million
Cash Flow
GBX 10.39 per share
Book Value
GBX 4.80 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£163.10 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/19/2018
Today
5/18/2022
Next Earnings (Estimated)
6/06/2022

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Redx Pharma (LON:REDX) Frequently Asked Questions

When is Redx Pharma's next earnings date?

Redx Pharma is scheduled to release its next quarterly earnings announcement on Monday, June 6th 2022.
View our earnings forecast for Redx Pharma
.

How were Redx Pharma's earnings last quarter?

Redx Pharma Plc (LON:REDX) released its earnings results on Monday, November, 19th. The company reported ($7.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($6.50) by $0.50.
View Redx Pharma's earnings history
.

Who are Redx Pharma's key executives?
Redx Pharma's management team includes the following people:
  • Ms. Lisa Mary Whewell Anson, CEO & Exec. Director (Age 52, Pay $644.74k)
  • Dr. James Mead, Chief Operating Officer (Age 44, Pay $132.67k)
  • Mr. Peter J. Collum, Chief Financial Officer
  • Dr. Richard Armer, Chief Scientific Officer
  • Dr. Karl Hard, Head of Investor Relations
  • Ms. Claire Solk, Gen. Counsel
  • Dr. Jane Robertson, Chief Medical Officer
  • Dr. Peter Bunyard, Head of Inflammation & Fibrosis
  • Dr. Cliff Jones, Head of Chemistry & DMPK
  • Dr. Caroline Phillips, Head of Oncology
What other stocks do shareholders of Redx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Redx Pharma investors own include Digital Globe Services (DGS), OptiBiotix Health (OPTI), TLA Worldwide (TLA), Be Heard Group plc (BHRD.L) (BHRD), Salesforce (CRM), (ECA), Carnival Co. & (CCL), Burberry Group (BRBY), boohoo group (BOO) and Bank of New York Mellon (BK).

What is Redx Pharma's stock symbol?

Redx Pharma trades on the London Stock Exchange (LON) under the ticker symbol "REDX."

How do I buy shares of Redx Pharma?

Shares of REDX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Redx Pharma's stock price today?

One share of REDX stock can currently be purchased for approximately GBX 59.25.

How much money does Redx Pharma make?

Redx Pharma has a market capitalization of £163.10 million and generates £10.04 million in revenue each year.

How many employees does Redx Pharma have?

Redx Pharma employs 71 workers across the globe.

What is Redx Pharma's official website?

The official website for Redx Pharma is redxpharma.com.

How can I contact Redx Pharma?

Redx Pharma's mailing address is Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom. The company can be reached via phone at +44-151-7064747.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.